Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | +2.89% | -1.19% | -16.72% |
Feb. 28 | Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024 | |
Feb. 28 | Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Nautilus Biotechnology, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Nautilus Biotechnology, Inc.
Goldman Sachs | |
Morgan Stanley | |
Cowen | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- NAUT Stock
- Consensus Nautilus Biotechnology, Inc.